EP2042179A1 - Novel therapeutic uses of adrenergic alpha-1 receptor antagonists - Google Patents

Novel therapeutic uses of adrenergic alpha-1 receptor antagonists Download PDF

Info

Publication number
EP2042179A1
EP2042179A1 EP07291148A EP07291148A EP2042179A1 EP 2042179 A1 EP2042179 A1 EP 2042179A1 EP 07291148 A EP07291148 A EP 07291148A EP 07291148 A EP07291148 A EP 07291148A EP 2042179 A1 EP2042179 A1 EP 2042179A1
Authority
EP
European Patent Office
Prior art keywords
adrenergic
receptor antagonist
bladder
treatment
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07291148A
Other languages
German (de)
French (fr)
Inventor
Pierangelo Geppetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to EP07291148A priority Critical patent/EP2042179A1/en
Priority to DK08833688.8T priority patent/DK2203170T3/en
Priority to PCT/IB2008/003126 priority patent/WO2009040671A1/en
Priority to PT08833688T priority patent/PT2203170E/en
Priority to ES08833688T priority patent/ES2373354T3/en
Priority to EP08833688A priority patent/EP2203170B1/en
Priority to JP2010526392A priority patent/JP5478495B2/en
Priority to SI200830471T priority patent/SI2203170T1/en
Priority to ARP080104131A priority patent/AR068825A1/en
Priority to MEP-2011-204A priority patent/ME01259B/en
Priority to AT08833688T priority patent/ATE524185T1/en
Priority to HR20110919T priority patent/HRP20110919T1/en
Priority to RS20110553A priority patent/RS52069B/en
Priority to PL08833688T priority patent/PL2203170T3/en
Publication of EP2042179A1 publication Critical patent/EP2042179A1/en
Priority to US12/730,559 priority patent/US8492396B2/en
Priority to CY20111101243T priority patent/CY1112203T1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Alfuzosine is a known adrenergic ⁇ -1 receptor antagonist that exhibits interesting muscle relaxant properties. Its use as anti-hypertensive agent was largely reported and it is currently administered for the treatment of the benign prostatic hyperplasia (BPH), also known as nodular hyperplasia, benign prostatic hypertrophy or benign enlargement of the prostate (BEP). Alfuzosine is also indicated in the treatment of the low urinary tract symptoms (LUTS). Although reduction in smooth muscle tone of the bladder-urethral functional unit is considered responsible for the beneficial effects of adrenergic ⁇ -1 receptor antagonists, various reports suggest that amelioration of storage LUTS cannot solely originate from the reduction of bladder outlet resistance.
  • BPH benign prostatic hyperplasia
  • LUTS low urinary tract symptoms
  • This inflammatory response include at the vascular level arteriolar vasodilatation (flare in the skin) and plasma protein extravasation and other tissue specific responses as smooth muscle contraction of urinary bladder, bronchi etc.
  • Neurogenic inflammation is considered to play a major role in different diseases of the urinary tract, including cystitis, prostatitis, overactive bladder syndrome (OAB) and detrusor overactivity ( Geppetti et al., 1996, Neurogenic inflammation. Boca Raton: CRC Press ).
  • Sympathetic afferents are known to modulate neurogenic inflammatory responses by interaction with primary afferent terminals.
  • Sympathectomy results in the reduction of C-fos expression in dorsal horn neurons induced by capsaicin ( Zou et al., 2002, Brain Res, 958, 322-9 ) and hyperalgesia induced by intradermal capsaicin is blocked by an ⁇ 1-adrenoceptor antagonist ( Kinnman et al., 1995, Neuroscience, 65, 283-91 ).
  • adrenergic ⁇ -1 receptor antagonists for treating "irritative" disorders of the urinary tract such as interstitial cystitis, overactive bladder or detrusor overactivity has not been suggested so far.
  • Interstitial cystitis or inflammatory bladder is a chronic inflammatory condition of the bladder. Unlike common cystitis, also known as urinary tract infection, IC is believed not to be caused by bacteria and does not respond to conventional antibiotic therapy. Its cause is not ascertained and there is currently no cure for IC. Symptoms include frequency and/or urgency to urinate and pain.
  • Overactive bladder syndrome sometimes called an 'irritable' bladder or 'detrusor instability'
  • detrusor overactivity are common conditions characterized by repeated and uncontrolled bladder contractions. Symptoms include urgency, frequency, nocturia and urge incontinence. Their causes are not fully understood although they are partially due to the defective behaviour of the detrusor. Bladder training is usually the main treatment, and medication (including antimuscarinic agents) does generally not alleviate all symptoms.
  • the present invention provides for the use of an adrenergic ⁇ -1 receptor antagonist or its pharmaceutically acceptable salts for the preparation of a medicament for treating and/or preventing inflammatory bladder, overactive bladder or detrusor overactivity.
  • said inflammatory bladder results from or is associated with interstitial cystitis.
  • the present invention provides for the use of an adrenergic ⁇ -1 receptor antagonist or its pharmaceutically acceptable salts for the preparation of a medicament for treating and/or preventing interstitial cystitis.
  • said adrenergic ⁇ -1 receptor antagonist is alfuzosine or its pharmaceutically acceptable salts, more preferably alfuzosine hydrochloride.
  • an effective amount of said adrenergic ⁇ -1 receptor antagonist, or of a pharmaceutically acceptable salt or solvate thereof, is administered to the patients who require such a treatment.
  • said patients are male patients.
  • Said adrenergic ⁇ -1 receptor antagonist above may be used at daily doses of 0.01 to 20 mg per kilo of body weight of the mammal to be treated, preferably at daily doses of from 0.1 to 10 mg/kg.
  • the dose may vary preferably from 0.5 mg to 1500 mg per day, in particular from 2.5 to 500 mg, depending on the age of the individual to be treated, the type of treatment, prophylactic or curative, and the seriousness of the disorder.
  • Said adrenergic ⁇ -1 receptor antagonists are generally administered as a dosage unit of 0.1 to 500 mg, preferably of 0.5 to 100 mg, of active principle, one to five times a day.
  • Preferable unit dosage forms comprise 2.5 or 10 mg of alfuzosine hydrochloride.
  • Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
  • compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, transdermal or rectal administration Said adrenergic ⁇ -1 receptor antagonists, and the pharmaceutically acceptable salts and solvates thereof, may be administered in unit administration forms, mixed with conventional pharmaceutical supports, to animals and humans for treating the abovementioned disorders.
  • the unit administration forms which are suitable comprise oral forms such as tablets, gel capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, subcutaneous, intramuscular or intravenous administration forms, local administration forms and rectal administration forms.
  • the main active ingredient is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
  • a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
  • the tablets may be coated with sucrose or other suitable materials, or they may be treated such that they have sustained or delayed activity and that they release, in a continuous manner, a predetermined amount of active principle.
  • Usual excipients include lactose monohydrate, microcrystalline cellulose, povidone, sodium carboxymethylstarch, magnesium stearate, ethylcellulose, hypromellose, macrogol 400, titane dioxide.
  • a preparation of gel capsules is obtained by mixing the active ingredient with a diluent and pouring the mixture obtained into soft or hard gel capsules.
  • a preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavour enhancer and a suitable colorant.
  • a sweetener preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavour enhancer and a suitable colorant.
  • the water-dispersible powders or granules may contain the active ingredient mixed with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, and also with sweeteners or flavour correctors.
  • the active principle is mixed into an excipient for preparing creams or ointments, or it is dissolved in a vehicle for intraocular administration, for example in the form of an eyewash.
  • suppositories prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
  • aqueous suspensions, saline solutions or injectable sterile solutions which contain pharmacologically compatible dispersion agents and/or wetting agents, for example propylene glycol or butylene glycol, are used.
  • the active principle may also be formulated in the form of microcapsules, optionally with one or more supports or additives.
  • cyclophosphamide 150 mg/kg, 48 h before is known to decrease bladder capacity and increased micturition frequency ( Maggi et al., 1992, J Auton Nerv Syst, 38, 201-8 ). These effects of cyclophosphamide were abolished in rats pretreated with capsaicin as adults ( Maggi et al., 1992, J Auton Nerv Syst, 38, 201-8 ). Thus, the inflammatory responses to cyclophosphamide are mediated by neurogenic inflammatory mechanisms.
  • Evans blue dye was used to measure plasma extravasation.
  • the proinflammatory stimulus was given immediately after the injection of the dye (30 mg/kg i.v. over 5s) in the jugular vein.
  • the chest was opened 10 min or at different time intervals as required after the injection of Evans blue and the animal perfused for 3 min with a phosphate buffer.
  • the urinary bladder, urethra and prostate were removed, blotted and weighed.
  • the tissue was then placed in 3 ml of formamide at 50 °C for 18 hr to extract the extravasated Evans blue dye.
  • the amount of Evans blue extravasated from the trachea and bronchi was measured using a spectrophotometer and expressed as ng/mg of wet weight.
  • Intravenous alfuzosin pretreatment (30 ⁇ g/kg) restored (> 50 % of reversal) the normal response to EFS.
  • a unitary dosage form of a compound of the invention in the form of a tablet may comprise the following constituents: Alfuzosine hydrochloride 5 mg Lactose 122 mg Microcristalline cellulose 36,0 mg Sodium carboxymethylstarch 7,0 mg Polyvidone 9 mg Magnesium stearate 1,0 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides for the use of an adrenergic α-1 receptor antagonist or its pharmaceutically acceptable salts for the preparation of a medicament for treating and/or preventing interstitial cystitis, overactive bladder or detrusor overactivity.

Description

  • Alfuzosine is a known adrenergic α-1 receptor antagonist that exhibits interesting muscle relaxant properties. Its use as anti-hypertensive agent was largely reported and it is currently administered for the treatment of the benign prostatic hyperplasia (BPH), also known as nodular hyperplasia, benign prostatic hypertrophy or benign enlargement of the prostate (BEP). Alfuzosine is also indicated in the treatment of the low urinary tract symptoms (LUTS). Although reduction in smooth muscle tone of the bladder-urethral functional unit is considered responsible for the beneficial effects of adrenergic α-1 receptor antagonists, various reports suggest that amelioration of storage LUTS cannot solely originate from the reduction of bladder outlet resistance.
  • Neuropeptides release from peripheral endings causes a series of inflammatory responses commonly referred to as neurogenic inflammation. This inflammatory response include at the vascular level arteriolar vasodilatation (flare in the skin) and plasma protein extravasation and other tissue specific responses as smooth muscle contraction of urinary bladder, bronchi etc. Neurogenic inflammation is considered to play a major role in different diseases of the urinary tract, including cystitis, prostatitis, overactive bladder syndrome (OAB) and detrusor overactivity (Geppetti et al., 1996, Neurogenic inflammation. Boca Raton: CRC Press).
  • The interaction between sympathetic nerves and cells of the immune system has been demonstrated in terms of distribution of tyrosine hydroxylase-positive fibers in lymphoid organs, expression of α-adrenoceptors on cells of the immune system, and immunomodulatory effects of the main sympathetic neurotransmitter noradrenaline (Feldman et al., 1987, J Immunol, 139, 3355-9; Madden et al., 1995, Annu Rev Pharmacol Toxicol, 35, 417-48). More recent findings show that noradrenaline exerts both a chemotactic and chemokinetic activity on immature dendritic cells and enhances spontaneous emigration of dendritic cells from skin explants. All these effects are blocked by αl-adrenoceptors antagonists (Maestroni, 2000, J Immunol, 165, 6743-7).
  • Sympathetic afferents are known to modulate neurogenic inflammatory responses by interaction with primary afferent terminals. Sympathectomy results in the reduction of C-fos expression in dorsal horn neurons induced by capsaicin (Zou et al., 2002, Brain Res, 958, 322-9) and hyperalgesia induced by intradermal capsaicin is blocked by an α1-adrenoceptor antagonist (Kinnman et al., 1995, Neuroscience, 65, 283-91). More recently, it has been shown that capsaicin-induced flare in the rat skin was reduced by an α1-adrenoceptor antagonist but not by a α2-adrenoceptor antagonist (Lin et al., 2003, J Neurophysiol, 89, 853-61). These studies suggest that intact sympathetic efferents modulate neurogenic inflammation in the skin and that peripheral α1-adrenoceptors play a major role in this modulation.
  • Nevertheless, the use of adrenergic α-1 receptor antagonists for treating "irritative" disorders of the urinary tract such as interstitial cystitis, overactive bladder or detrusor overactivity has not been suggested so far.
  • Interstitial cystitis (IC) or inflammatory bladder is a chronic inflammatory condition of the bladder. Unlike common cystitis, also known as urinary tract infection, IC is believed not to be caused by bacteria and does not respond to conventional antibiotic therapy. Its cause is not ascertained and there is currently no cure for IC. Symptoms include frequency and/or urgency to urinate and pain.
  • Overactive bladder syndrome (sometimes called an 'irritable' bladder or 'detrusor instability') and detrusor overactivity are common conditions characterized by repeated and uncontrolled bladder contractions. Symptoms include urgency, frequency, nocturia and urge incontinence. Their causes are not fully understood although they are partially due to the defective behaviour of the detrusor. Bladder training is usually the main treatment, and medication (including antimuscarinic agents) does generally not alleviate all symptoms.
  • It is therefore highly desirable to provide new medicines for the treatment and/or prevention of the above disorders.
  • According to a first object, the present invention provides for the use of an adrenergic α-1 receptor antagonist or its pharmaceutically acceptable salts for the preparation of a medicament for treating and/or preventing inflammatory bladder, overactive bladder or detrusor overactivity.
  • Preferably, said inflammatory bladder results from or is associated with interstitial cystitis. According to a preferred aspect, the present invention provides for the use of an adrenergic α-1 receptor antagonist or its pharmaceutically acceptable salts for the preparation of a medicament for treating and/or preventing interstitial cystitis.
  • According to a preferred aspect, said adrenergic α-1 receptor antagonist is alfuzosine or its pharmaceutically acceptable salts, more preferably alfuzosine hydrochloride.
  • For the uses of the invention, an effective amount of said adrenergic α-1 receptor antagonist, or of a pharmaceutically acceptable salt or solvate thereof, is administered to the patients who require such a treatment. Preferably, said patients are male patients.
  • Said adrenergic α-1 receptor antagonist above, and the pharmaceutically acceptable salts and solvates thereof, may be used at daily doses of 0.01 to 20 mg per kilo of body weight of the mammal to be treated, preferably at daily doses of from 0.1 to 10 mg/kg. In humans, the dose may vary preferably from 0.5 mg to 1500 mg per day, in particular from 2.5 to 500 mg, depending on the age of the individual to be treated, the type of treatment, prophylactic or curative, and the seriousness of the disorder. Said adrenergic α-1 receptor antagonists are generally administered as a dosage unit of 0.1 to 500 mg, preferably of 0.5 to 100 mg, of active principle, one to five times a day. Preferable unit dosage forms comprise 2.5 or 10 mg of alfuzosine hydrochloride.
  • Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
  • In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, transdermal or rectal administration, Said adrenergic α-1 receptor antagonists, and the pharmaceutically acceptable salts and solvates thereof, may be administered in unit administration forms, mixed with conventional pharmaceutical supports, to animals and humans for treating the abovementioned disorders. The unit administration forms which are suitable comprise oral forms such as tablets, gel capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, subcutaneous, intramuscular or intravenous administration forms, local administration forms and rectal administration forms.
  • When a solid composition in the form of tablets is prepared, the main active ingredient is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets may be coated with sucrose or other suitable materials, or they may be treated such that they have sustained or delayed activity and that they release, in a continuous manner, a predetermined amount of active principle. Usual excipients include lactose monohydrate, microcrystalline cellulose, povidone, sodium carboxymethylstarch, magnesium stearate, ethylcellulose, hypromellose, macrogol 400, titane dioxide.
  • A preparation of gel capsules is obtained by mixing the active ingredient with a diluent and pouring the mixture obtained into soft or hard gel capsules.
  • A preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably a calorie-free sweetener, methylparaben and propylparaben as antiseptics, and also a flavour enhancer and a suitable colorant.
  • The water-dispersible powders or granules may contain the active ingredient mixed with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, and also with sweeteners or flavour correctors.
  • For local administration, the active principle is mixed into an excipient for preparing creams or ointments, or it is dissolved in a vehicle for intraocular administration, for example in the form of an eyewash.
  • For rectal administration, use is made of suppositories prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
  • For parenteral administration, aqueous suspensions, saline solutions or injectable sterile solutions which contain pharmacologically compatible dispersion agents and/or wetting agents, for example propylene glycol or butylene glycol, are used.
  • The active principle may also be formulated in the form of microcapsules, optionally with one or more supports or additives.
  • The following examples further illustrate the present invention:
    • EXAMPLES In vivo assay
  • Male Sprague-Dawley rats and Swiss mice were administered with CYP (150 mg/kg, i.p.) or its vehicle (0.9% NaCl) for cystitis induction. 48 hours later urinary bladders were removed and placed in an organ bath for motor response measurement. Writhing behaviors and plasma protein extravasation were investigated 90 min after the CYP administration.
    • Isolated strips of rat urinary bladder
  • Strips of rat urinary bladder were taken from terminally anesthetized animals and mounted in organ baths and after an equilibration period the eNANC contractile response to electrical field stimulation (EFS, 5 Hz, 1 ms width, 10 V) in the absence and presence of atropine (1 µM) is studied (Rigoni et al., 2003, Br J Pharmacol, 138, 977-85) The contraction produced by EFS in these experimental conditions is entirely mediated by SP and NKA released from terminals of primary sensory neurons. The eNANC response to EFS was reproducible at 60 min intervals. The effect of alfuzosin or its vehicle on the eNANC response to EFS was studied in parallel experiments. At the beginning or end of each experiment tissues were challenged with carbachol (1 µM). The effect of alfuzosin was studied also in bladder strips obtained from rats treated with cyclophosphamide.
    • Drug administration
  • Intraperitoneal administration of cyclophosphamide (150 mg/kg, 48 h before) is known to decrease bladder capacity and increased micturition frequency (Maggi et al., 1992, J Auton Nerv Syst, 38, 201-8). These effects of cyclophosphamide were abolished in rats pretreated with capsaicin as adults (Maggi et al., 1992, J Auton Nerv Syst, 38, 201-8). Thus, the inflammatory responses to cyclophosphamide are mediated by neurogenic inflammatory mechanisms.
    • Plasma Extravasation
  • Evans blue dye was used to measure plasma extravasation. The proinflammatory stimulus was given immediately after the injection of the dye (30 mg/kg i.v. over 5s) in the jugular vein. The chest was opened 10 min or at different time intervals as required after the injection of Evans blue and the animal perfused for 3 min with a phosphate buffer. The urinary bladder, urethra and prostate were removed, blotted and weighed. The tissue was then placed in 3 ml of formamide at 50 °C for 18 hr to extract the extravasated Evans blue dye. The amount of Evans blue extravasated from the trachea and bronchi was measured using a spectrophotometer and expressed as ng/mg of wet weight.
  • Results shown that CYP-evoked plasma protein extravasation in urinary bladder was completely prevented by two putative TRPA1 antagonist, ruthenium red (4 mg/kg, s.c.) and camphor (50 µmol/kg i.p.).
  • In addition, in isolated urinary bladder strips, the contractile response to electrical field stimulation in the presence of atropine (eNANC) was reduced in urinary bladders taken from CYP-treated rats as compared to bladders from vehicle-treated rats.
  • Intravenous alfuzosin pretreatment (30 µg/kg) restored (> 50 % of reversal) the normal response to EFS.
  • Similarly, the contractile response to capsaicin was reduced in urinary bladder taken from CYP-treated rats, was partially restored by pretreatment with alfuzosin (∼50% of reversal). In contrast, the response to carbachol or SP were not affected by in vivo CYP administration. Finally, the number of writhings evoked in mice by intraperitoneal injection of acetic acid (10.3 ± 0.6) was increased by ∼ 50% by CYP administration, an effect that was significantly inhibited by pretreatment alfuzosin (30 µg/kg, i.v., 48 % of reduction).
  • It was thus confirmed in vivo that the ability of CYP to activate sensory nerve terminal inducing urinary bladder inflammation is mediated by TRPA1 activation. This inflammatory mechanism may result in the depletion of proinflammatory neuropeptides. Blockade of the α1-adrenergic receptor on sensory terminals regulates this phenomenon preventing the inflammatory response and neuropeptide depletion α1-adrenoreceptor blockade by alfuzosin also inhibits nociceptor sensitization induced by CYP treatment. These results offer a mechanistic explanation to the use of alfuzosin in the treatment of different conditions of the lower urinary tract characterized by irritation and pain symptoms.
    • Pharmaceutical composition according to the invention
  • As a representative example, a unitary dosage form of a compound of the invention in the form of a tablet may comprise the following constituents:
    Alfuzosine hydrochloride 5 mg
    Lactose 122 mg
    Microcristalline cellulose 36,0 mg
    Sodium carboxymethylstarch 7,0 mg
    Polyvidone 9 mg
    Magnesium stearate 1,0 mg

Claims (9)

  1. Use of an adrenergic α-1 receptor antagonist for the preparation of a medicament for the treatment and/or prevention of inflammatory bladder.
  2. Use according to claim 1, wherein said inflammatory bladder results from or is associated with interstitial cystitis.
  3. Use of an adrenergic α-1 receptor antagonist for the preparation of a medicament for the treatment and/or prevention of overactive bladder syndrome.
  4. Use of an adrenergic α-1 receptor antagonist for the preparation of a medicament for the treatment and/or prevention of detrusor overactivity.
  5. Use according to anyone of the preceding claims, wherein said adrenergic α-1 receptor antagonist is alfuzosine or its pharmaceutically acceptable salts.
  6. Use according to anyone of the preceding claims, wherein said adrenergic α-1 receptor antagonist is alfuzosine hydrochloride.
  7. Use according to anyone of the preceding claims for the treatment and/or prevention in male patients.
  8. An adrenergic α-1 receptor antagonist for the treatment and/or prevention of disorders selected from the group consisting in inflammatory bladder, overactive bladder syndrome, detrusor overactivity.
  9. An adrenergic α-1 receptor antagonist according to claim 7 which is alfuzosine or its pharmaceutically acceptable salts.
EP07291148A 2007-09-26 2007-09-26 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists Withdrawn EP2042179A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP07291148A EP2042179A1 (en) 2007-09-26 2007-09-26 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
SI200830471T SI2203170T1 (en) 2007-09-26 2008-09-24 NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE
AT08833688T ATE524185T1 (en) 2007-09-26 2008-09-24 NEW THERAPEUTIC USE OF ALFUZOSINE
PT08833688T PT2203170E (en) 2007-09-26 2008-09-24 Novel therapeutic uses of adrenergic alfuzosine
ES08833688T ES2373354T3 (en) 2007-09-26 2008-09-24 NEW THERAPEUTIC USES OF ADREGENIC ALFUZOSINE.
EP08833688A EP2203170B1 (en) 2007-09-26 2008-09-24 NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE
JP2010526392A JP5478495B2 (en) 2007-09-26 2008-09-24 Novel therapeutic use of adrenergic alpha-1 receptor antagonists
DK08833688.8T DK2203170T3 (en) 2007-09-26 2008-09-24 Novel therapeutic uses of adrenergic alfuzosin
ARP080104131A AR068825A1 (en) 2007-09-26 2008-09-24 THERAPEUTIC USES OF ANTAGONISTS OF THE ALFA-1 ANDRENERGIC RECEIVER
MEP-2011-204A ME01259B (en) 2007-09-26 2008-09-24 NEW THERAPEUTIC USE OF ADRENERGIC ALFUZOSIN
PCT/IB2008/003126 WO2009040671A1 (en) 2007-09-26 2008-09-24 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
HR20110919T HRP20110919T1 (en) 2007-09-26 2008-09-24 NEW USE OF ALFUZOSIN IN THERAPY
RS20110553A RS52069B (en) 2007-09-26 2008-09-24 NEW THERAPEUTIC USE OF ADRENERGIC ALFUZOSIN
PL08833688T PL2203170T3 (en) 2007-09-26 2008-09-24 NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE
US12/730,559 US8492396B2 (en) 2007-09-26 2010-03-24 Therapeutic uses of adrenergic α-1 receptor antagonists
CY20111101243T CY1112203T1 (en) 2007-09-26 2011-12-14 ADVERTISING THERAPEUTIC USES OF ADRENergic alfuzosin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291148A EP2042179A1 (en) 2007-09-26 2007-09-26 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists

Publications (1)

Publication Number Publication Date
EP2042179A1 true EP2042179A1 (en) 2009-04-01

Family

ID=38754714

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07291148A Withdrawn EP2042179A1 (en) 2007-09-26 2007-09-26 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
EP08833688A Active EP2203170B1 (en) 2007-09-26 2008-09-24 NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08833688A Active EP2203170B1 (en) 2007-09-26 2008-09-24 NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE

Country Status (15)

Country Link
US (1) US8492396B2 (en)
EP (2) EP2042179A1 (en)
JP (1) JP5478495B2 (en)
AR (1) AR068825A1 (en)
AT (1) ATE524185T1 (en)
CY (1) CY1112203T1 (en)
DK (1) DK2203170T3 (en)
ES (1) ES2373354T3 (en)
HR (1) HRP20110919T1 (en)
ME (1) ME01259B (en)
PL (1) PL2203170T3 (en)
PT (1) PT2203170E (en)
RS (1) RS52069B (en)
SI (1) SI2203170T1 (en)
WO (1) WO2009040671A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110933933B (en) * 2018-07-18 2022-12-27 温州医科大学 Method for treating myopia and application of prepared medicine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198136A1 (en) * 2001-03-06 2002-12-26 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
WO2004017960A1 (en) * 2002-08-14 2004-03-04 Janssen Pharmaceutica N.V. Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
US20050187222A1 (en) * 1996-02-02 2005-08-25 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (en) * 1985-05-28 1988-08-05 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING ALFUZOSINE
WO1999002215A1 (en) * 1997-07-10 1999-01-21 Therakos, Inc. Treatment of inflammatory disorders of the bowel and urinary bladder
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2002062389A1 (en) * 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
MXPA05013905A (en) * 2003-07-02 2006-02-24 Hoffmann La Roche Arylamine-substituted quinazolinone compounds.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187222A1 (en) * 1996-02-02 2005-08-25 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds
US20020198136A1 (en) * 2001-03-06 2002-12-26 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
WO2004017960A1 (en) * 2002-08-14 2004-03-04 Janssen Pharmaceutica N.V. Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE NUNZIO ET AL: "The Evolution of Detrusor Overactivity After Watchful Waiting, Medical Therapy and Surgery in Patients with Bladder Outlet Obstruction", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 169, no. 2, February 2003 (2003-02-01), pages 535 - 539, XP005536451, ISSN: 0022-5347 *
INTERSTITIAL CYSTITIS ASSOCIATION; TREATMENT GUIDELINES, May 2005 (2005-05-01), XP002461515, Retrieved from the Internet <URL:http://www.ichelp.org/PatientInformation/TreatmentOptions/TreatmentGuidelines/tabid/85/Default.aspx> [retrieved on 20071207] *
KAPLAN ET AL: "Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction", EUROPEAN UROLOGY, S. KARGER AG., BASEL, CH, vol. 51, no. 6, 26 April 2007 (2007-04-26), pages 1717 - 1723, XP022048289, ISSN: 0302-2838 *

Also Published As

Publication number Publication date
SI2203170T1 (en) 2012-01-31
ME01259B (en) 2013-06-20
WO2009040671A4 (en) 2009-05-28
US20110009436A1 (en) 2011-01-13
JP2010540511A (en) 2010-12-24
CY1112203T1 (en) 2015-12-09
WO2009040671A1 (en) 2009-04-02
PT2203170E (en) 2011-12-27
EP2203170B1 (en) 2011-09-14
DK2203170T3 (en) 2012-01-16
AR068825A1 (en) 2009-12-09
HRP20110919T1 (en) 2012-01-31
JP5478495B2 (en) 2014-04-23
ATE524185T1 (en) 2011-09-15
RS52069B (en) 2012-06-30
EP2203170A1 (en) 2010-07-07
ES2373354T3 (en) 2012-02-02
US8492396B2 (en) 2013-07-23
PL2203170T3 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
KR20200065113A (en) Anticholinergic neuroprotective composition and methods
EP0912184B1 (en) Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US20050026977A1 (en) Zonisamide use in eating disorders
AU2012380583B2 (en) Pharmaceutical composition for the prophylaxis and treatment of psychological, behavioral and cognitive disorders
ZA200608241B (en) Use of peptidic compounds for the prophylaxis and treatment of chronic headache
KR20190016478A (en) Treatment of multiple sclerosis using LSD1 inhibitor
RU2308268C2 (en) Derivatives of aryl- or heteroarylazolyl carbinols for treating incontinence of urine
US8492396B2 (en) Therapeutic uses of adrenergic α-1 receptor antagonists
KR20130131265A (en) Composition for preventing or treating irritable bowel syndrome
RU2330649C2 (en) Agonists of alpha-2b or 2b/2c adrenoreceptors for neurodegenerative diseases treatment
US20040142929A1 (en) Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
EA028616B1 (en) USE OF p75 RECEPTOR ANTAGONISTS FOR TREATING OVERACTIVE BLADDER
CN105579036A (en) Agents for improving vesicourethral dyssynergia
Ghaith et al. Investigational agents for the irritable bowel syndrome
US20090247461A1 (en) Methods for therapeutic treatment of pain
EP1728508A1 (en) Medicine for prevention or treatment of frequent urination or urinary incontinence
WO2018116293A1 (en) Low dose drug combinations for use in preventing and treating neuronal damage
Tai et al. Sinomenine
US20260027175A1 (en) Compositions and methods for treating a cognitive deficit
Abdulmajed et al. Antikolinerjik ilaçların mesane üzerinde ki etki mekanizması nedir–nörojenik mi yoksa non-nörojenik mi?
Galeano et al. Urodynamic action of clonidine in the chronic spinal cat
KR100884647B1 (en) A pharmaceutical composition comprising a substituted benzene derivative compound having a therapeutic effect and a brain protective effect on brain neurological diseases including Parkinson&#39;s disease, and a method for treating brain diseases using the compound
HK1018745B (en) Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
EA043344B1 (en) COMPOSITION OF PARACETAMOL: AMITRYPTYLINE WITH A FIXED DOSE AND METHOD FOR TREATING MIXED CANCER PAIN

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20090701

AKX Designation fees paid

Designated state(s): FR

17Q First examination report despatched

Effective date: 20091218

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100629